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 When Rheumatology and Infectious 
Disease Come Together
Introduction
Hidradenitis suppurativa (HS) is a chronic 
inflammatory skin disease characterized by sub-
cutaneous painful nodules1 affecting areas rich in 
apocrine glands such as axillary, inguinal, genital, 
and infra-mammary regions.2 The inflamed 
glands result into pus secretion and eventually to 
scar, fistula, sinuses, or abscess formation.3,4 Its 
frequency has a wide range among different eth-
nic subgroups,2,5 but on average is estimated to be 
around 0.5–4%.2,3,6,7
Epidemiology
HS remains generally under-recognized,8 espe-
cially if not presented to dermatologists, affecting 
the overall reported prevalence and incidence 
figures. This is despite its very distinct clinical 
presentation and the possibility to achieve a reli-
able diagnosis even based on simple questioning.9 
Prevalence figures are also affected by the nature 
of the studies undertaken, population studied, 
and geographical location.10 With a prevalence of 
up to 4%, HS is therefore frequent, especially in 
post-pubescent women.8,11 However, the onset of 
HS has been described also in prepubertal chil-
dren as well as postmenopausal women.7,12 The 
female:male ratio is approximately 3:1, with 
women showing a greater likelihood of having 
genitofemoral lesions.13 The prevalence of HS 
appears to decline after the age of 50 years.7 
Around a third of patients report a positive family 
history for HS, with an autosomal dominant pat-
tern of inheritance.14,15 Family history has been 
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associated with early onset HS.16 Many genes 
have been implicated in the pathogenesis of the 
disease with these encoding for expression of the 
subunits of γ-secretase complex being the most 
well described.2 Single nucleotide polymorphisms 
in the promoter region of the tumor necrosis fac-
tor (TNF) gene have also been linked with HS.17
Associations with metabolic disease, 
autoimmune rheumatic diseases, and other 
conditions
Associations have been reported with various 
factors and habits that belong in the cardio- 
metabolic spectrum, such as obesity, diabetes 
mellitus, dyslipidemia, hypertension, and smok-
ing.7,18,19 Smoking has been linked with worse dis-
ease in HS.20 Similarly, a strong association has 
been found between body mass index (BMI) and 
disease severity of HS, with more severe HS seen 
in obese compared with overweight patients.20 A 
possible metabolic loop has in fact been described 
linking insulin resistance and HS, with altered 
mammalian target of rapamycin (mTOR), the 
latter reported in metabolic and autoimmune dis-
orders. More specifically, mTOR has been found 
to be increased in lesional as well as nonlesional 
skin of HS patients and mTOR gene expression 
correlated with the severity of HS. Evidence also 
implicates mTOR in insulin resistance seen in 
patients with HS,21 further supporting the con-
cept of a metabolic loop linking HS, BMI, and 
insulin resistance. This disease ‘behavior’ and 
association with BMI and obesity has also been 
reported in other inflammatory skin and joint 
conditions such as psoriasis and rheumatoid and 
psoriatic arthritis (PsA).22–26 Common proinflam-
matory pathways seem to be the culprit in these 
observed associations.27 For example, upregula-
tion of conventional cytokines [e.g. TNFα and 
interleukin (IL)-17] and adipokines (e.g. 
chemerin, visfatin, leptin, and adiponectin) have 
been reported in psoriasis and adiposity.28 Studies 
have shown a relationship between adiponectin 
and psoriasis, but a relationship that depends on 
the presence of obesity.29 Adiponectin, a cytokine 
produced by adipose tissue at levels inversely pro-
portional to BMI and waist:hip ratio, induces the 
release of pro-inflammatory cytokines IL-1 and 
IL-10 and inhibits the cytokines IL-6 and TNFα, 
the latter two well-recognized for their role in 
inflammation for example, in the setting of rheu-
matoid arthritis (RA). In the case of leptin, 
another pro-inflammatory cytokine derived from 
adipocytes, its circulating levels have been 
correlated directly with body fat mass.30 
Therapeutic strategies targeting all aspects of dis-
ease, including skin and joint involvement in the 
case of psoriasis and PsA as well as obesity, are 
recommended. Of note, a higher prevalence of 
metabolic syndrome has also been noted in 
patients with HS compared with controls, sug-
gesting that metabolic abnormalities may be a 
contributing factor in the development of HS, 
particularly in younger patients.31 Similar associa-
tions have been identified in psoriasis possibly 
due to commonalities in the mechanistic path-
ways underlying both skin conditions.32,33 
Interestingly, obesity also seems to negatively 
affect the response to biologic therapy in these 
conditions.34 In line with these observations, 
weight loss has been associated with improved 
inflammatory states in autoimmune rheumatic 
diseases such as PsA, supporting the hypothesis 
of obesity as a promotor of disease activity in 
PsA.23 In the case of HS, reports on nonpharma-
cologic approaches to therapy that include weight 
loss are limited by the small study size and the 
general lack of randomized controlled trials.35 
However, a recent multicenter, observational, 
crossover, pilot study has shown no association of 
the improvement in disease severity with weight 
loss.36
Inflammatory bowel disease is also a frequent 
comorbidity in HS.37 A study has shown that 
17% of patients with Crohn’s disease are affected 
by HS.38 Clinical, histologic and epidemiologic 
similarities (e.g. sinus tracts, granulomatous 
inflammation, scarring and post-pubertal onset) 
support this association.38 In addition, it has been 
also suggested that mood disorders such as 
depression and anxiety are also more frequent in 
these patients.1,39,40
With regard to autoimmune inflammatory joint 
disease, rheumatoid factor negative, and HLA-
B27 negative joint disease appears to be more fre-
quent among patients with HS compared with the 
general population, often with asymmetrical 
peripheral joint involvement.41 Interestingly, how-
ever, recent evidence from a cross-sectional study 
in patients from the Groningen Leeuwarden Axial 
Spondylarthritis (GLAS) cohort, fulfilling the 
Assessment of Spondylarthritis International 
Society (ASAS) criteria for axial spondyloarthrop-
athy (SpA) (79% HLA-B27 positive), shows HS to 
be more prevalent than in the general population 
(9.1% versus 0.053–4.1%).42 Reports also exist of 
the coexistence of HS with other autoimmune 
CA Constantinou, GE Fragoulis et al.
journals.sagepub.com/home/tab 3
rheumatic diseases such as systemic lupus erythe-
matosus (SLE)43 and SAPHO (synovitis, acne, 
pustulosis, hyperostosis, and osteitis) syndrome,44 
further supporting the notion of a possible com-
mon denominator in disease pathogenesis.
Pathogenesis
General aspects
The pathogenesis of HS is not entirely clear and 
possibly represents a dysregulated immune 
response to skin microbiota, in a susceptible 
genetic background.1 There is some evidence that 
keratinocytes may be also intrinsically dysfunc-
tional,45 while it is unknown whether bacterial 
infections are per se the primary cause or a contrib-
uting factor to this clinical condition.1 It is cur-
rently debated which is the initiating event in the 
pathogenesis of HS. Current hypothesis suggests 
that infundibular hyperkeratosis, follicular epithe-
lium hyperplasia, and perifolliculitis come first.46 
These lead to possible bacterial biofilm forma-
tion,1 distention and rupture of the terminal hair 
follicles (HFs), and subsequently to spillage of 
material (such as keratin or hair-shafts) from 
pilosebaceous unit to the dermis.2,4 These act as 
danger signals initiating the immune response and 
recruiting various cells including macrophages, B 
and T lymphocytes, and neutrophils.2
As mentioned above, genetic factors play signifi-
cant role in the pathogenesis of the disease. 
Familiar cases are associated with loss of func-
tion mutations for genes encoding proteins in the 
γ-secretase complex.47 γ-secretase plays a signifi-
cant role in the Notch signal transduction, as it 
mediates the intramembrane cleavage of the latter 
and subsequent release of the intracellular domain 
of Notch (NICD).48 Notch plays a significant role 
in the HF and hair cycle homeostasis48,49 regulat-
ing also keratinocyte (KC) differentiation and 
proliferation.49–51 It also seems to be important 
for the development and function of natural killer 
(NK) and T-regulatory (Treg) cells.47,52 It is not 
known what the exact role of Notch is in patho-
genesis for HS. Some investigators have sug-
gested that Notch dysregulation might be an 
epiphenomenon related to the observed aberran-
cies in keratinocytes proliferation.53
Tregs have been found to promote the prolifera-
tion and differentiation of HF stem cells, which is 
critical for HF maintenance and regeneration.47,54 
A high T-helper-17 (Th17)/Tregs ratio has been 
observed in the skin of patients with HS. This, 
was normalized after treatment with anti-TNF 
reagents.55 Interestingly, an imbalance in the 
Th17/Tregs ratio has been found in obesity and 
other conditions associated with HS, as men-
tioned previously, such as smoking, depression, 
and inflammatory bowel diseases.47
What happens at the lesion?
Histopathology. Lesions of HS are characterized by 
infiltrates of white blood cells. It has been sug-
gested that in early lesions, neutrophilic abscesses 
along with macrophages, monocytes, and dendritic 
cells predominate, whereas in chronic lesions one 
can note more B lymphocytes and plasma cells.56
Cytokines-role of TNF, IL-17, and IL-1. Pro-
inflammatory (IL-1β, TNF, IL-17) as well as anti-
inflammatory cytokines (IL-10) are found to be 
increased in HS lesional and per-lesional skin 
compared with healthy donors or patients with 
psoriasis56,57 (Figure 1). Interferon (IFN)-γ is also 
increasingly expressed in the skin of HS patients 
compared with healthy individuals.1,50 However, 
this finding has not been confirmed by all 
investigators.55
TNF is produced by dendritic cells and mac-
rophages and its levels are associated with HS 
severity.1 IL-17 is produced by neutrophils,58 
Th17 cells,59 or other cells capable for its produc-
tion.47 In agreement, high levels of IL-23 (which 
drives IL-17 production) have been also found to 
be increased in HS lesions59 produced by mac-
rophages and dendritic cells.1
It has been suggested that IL-17 might drive pro-
duction of IL1-β by KCs via activation of the 
nucleotide-binding oligomerization domain, leu-
cine-rich repeat and pyrin domain containing 
(NLRP3) protein of inflammasome and cas-
pase-1.58,60 Both are increased in the epidermis of 
HS patients. IL-18 regulated by caspase-1 and 
NLRP3 was also found increased in HS skin.57 It 
has been hypothesized that keratin fibers and 
other debris as well as damage-associated molec-
ular pattern molecules (DAMPS) or pathogen-
associated molecular pattern molecules (PAMPS) 
can also activate the inflammasome.1,56 It has also 
been suggested that IL-17 induces the production 
of S100A8 and S100A9 by KCs, which are 
increased in lesional but not perilesional skin in 
HS58 and are also expressed by macrophages and 
neutrophils.50 Of note, they are also increased in 
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the serum of HS patients.58 These proteins, in 
turn, can augment KC proliferation and expres-
sion of pro-inflammatory cytokines and 
chemokines.58 In addition, there are data sup-
porting that KCs intrinsically produce increased 
levels of IL-1.50 It is possible that there is a posi-
tive feedback loop between IL-1 and IL-17.1 To 
add another level of complexity, IL-36 family 
members which belong to the IL-1 family are also 
increased systemically and locally expressed by 
KCs and macrophages.61 These are able to medi-
ate Th1 and Th17 responses as well as KC prolif-
eration.61,62 Finally, a recent study demonstrated 
that IL-26 is increased in plasma and skin of HS 
patients.63 IL-26 is a cytokine expressed mainly 
by Th17 cells but also from other cell types such 
as innate lymphoid cells 3 (ILC3), and belongs in 
the IL-20 subfamily.63,64 It leads to the produc-
tion of pro-inflammatory cytokines through liga-
tion to its receptors (IL-10R2 and IL-20R1) but 
it can also bind to cell-free DNA and subse-
quently activate Toll-like receptors pathways. In 
addition, it exerts direct antimicrobial properties 
having the ability to open pores in bacterial mem-
branes.63,64 Scala et al. showed that inhibition of 
IL-26, decreased IL-1β, IL-6 as well as human 
β-defensin-2 (HBD-2) and human β-defensin-3 
(HBD-3) genes expression, in skin, leaving unaf-
fected those encoding for IL-17 and IL-23.63 
Interestingly, antimicrobial, cytotoxic, and phago-
cytic ability from peripheral blood mononuclear 
cells (PBMCs) obtained from HS patients was 
impaired, implying that IL-26 might be dysfunc-
tional in these patients.63
In contrast, IL-22 is relatively decreased in 
HS.50,65 KCs from HS patients produced less 
IL-22 compared with those of healthy donors.45 
IL-22 deficiency has also been linked to increased 
IL-10 production,65 which might be induced, 
among others by IL-1β.65 It is also worth men-
tioning that IL-22 production is enhanced by 
Notch signaling, which is defective in some HS 
patients.50 In human intestinal epithelial cells, it 
has been shown that IL-22, through the forced 
expression of the Notch target gene Hes1 and 
subsequent phosphorylation of signal transducer 
and activator of transcription (STAT)-3, 
induced the genes encoding for antimicrobial 
peptides (AMPs) such as REG1A, REG3A, and 
REG3G.66
Matrix metalloproteinases and AMPs. Overex-
pression of matrix-metalloproteinases (MMP; 
especially MMP-2 and MMP-8) has been 
observed in lesional skin of patients with HS3,67,68 
partly explaining the derangement of extracellular 
matrix and the respective morphological changes.3 
In a recent study, it was found that MMP-8 was 
secreted in HS skin by accumulating granulo-
cytes, driven by TNF.69 The latter was found to 
also increase the expression of MMP-8 by dermal 
Figure–1. Molecules involved in the lesions of hidradenitis suppurativa, at a glance. At the upper right corner 
are summarized the main alterations observed.
DAMP, damage-associated molecular pattern; DC, dendritic cells; KC, keratinocytes; IL, interleukin; MF, macrophages; 
MMP, matrix metalloproteinases; PAMP, pathogen-associated molecular pattern (e.g. keratin, debris); PMN, 
polymorphonuclear; TNF, tumor necrosis factor; Th, T-helper.
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fibroblasts. Providing another hint for the link 
between HS and metabolic diseases, Tsaousi et al. 
found a negative correlation between MM8 blood 
levels (which were also increased) and high-den-
sity lipoprotein (HDL) blood levels.69 For the for-
mer, a positive correlation with resistin is also 
reported.69 To be mentioned, resistin is one of the 
key adipokines increased in obese patients. It is 
considered as an inflammatory mediator and has 
been reported to be increased in patients with 
inflammatory arthritis similarly to PsA and anky-
losing spondylitis.25 In addition, IL-17 could be 
related with augmented MMPs production, as it 
has been shown previously for fibroblast-like syn-
oviocytes from patients with enthesitis-related 
arthritis.70
AMPs seem to also have a role in HS. There is 
relative deficiency of AMPs in HS lesions, com-
pared with skin from psoriasis or atopic dermati-
tis patients.65 This could be related to the lower 
IL-22 and IL-20 levels in HS lesions, both regu-
lating along with other factors (e.g. IL-17) AMP 
production.65 It has been shown that there are 
alterations in the pattern of the AMP produced 
by isolated KC from HS patients compared with 
healthy donors, further supporting the notion for 
an intrinsic defect of these cells.50 Transcriptome 
analyses have shown that expression of the 
AMPs dermcidin and ribonuclease-7 were 
downregulated in HS lesional skin compared to 
skin form healthy donors.71,72 The role of der-
mcidin was further highlighted in another tran-
scriptome analyses, in which the gene encoding 
for this AMP was one of the top downregulated 
genes in HS lesions compared with nonlesional 
skin from the same patients.73 On the other 
hand, in HS lesions compared with healthy skin 
from the same patients, mRNA levels of several 
AMPs such as HBD-2, S100A7 (psoriasin), 
S100A7A (koebnerisin) and LL-37 were found 
to be increased.73–75 LL-37 (cathelicidin) can be 
produced by many different cell types including 
resident cells such as keratinocytes and immune 
cells. Its levels were correlated with presence of 
immune cells such as neutrophils, macrophages, 
and T cells.4 It acts as chemo-attractant, aug-
menting also pro-inflammatory responses, 
upregulating costimulatory molecules expres-
sion by DCs and increasing the production of 
pro-inflammatory cytokines 4 Expression of 
AMPs might also vary, with regard to the sever-
ity of HS. Hofmann et al.72 found that HBD-3 
was upregulated in HS but not in patients with 
Hurley grade III.
Serum
At a peripheral blood level, inflammation markers 
such as C-reactive protein (CRP) and several 
cytokines, most of them are pro-inflammatory, are 
found to be elevated in HS patients. In fact, it is 
generally observed that IL-1, IL-6, IL-8, IL-12p70, 
IL-17, soluble TNF receptor II (sTNF-RII), 
TNF-a, and IL-10 are found to be elevated in the 
peripheral blood of these patients.18,76–79 Recently, 
it was suggested that IL-26 is also increased.63 
Various studies have shown that levels of the pro-
inflammatory cytokines and CRP go in parallel 
with disease18,76,77,79 and mirror response to treat-
ment.18 In addition, a small study has suggested 
that baseline IL-6 and CRP levels can serve as 
negative predictors for response to infliximab;80 
and the frequency of T cells secreting IL-17 and 
IL-22 is increased in the peripheral blood of 
patients with HS compared with that of healthy 
donors.50 IL-17 leads to chemokine production, 
which, in turn, recruit leukocytes (e.g. mac-
rophages, neutrophils) at the site of inflamma-
tion.81 In addition, they augment the production of 
IL-1β and IL-6 providing a positive feedback loop 
for Th17 cells development and subsequent IL-17 
production81 and regulate AMP production. On 
the other hand, it has to be mentioned that there 
are some possibly contradictory data.82,83 Kanni 
et al. have shown that isolated PBMCs produced 
lower levels of the above-mentioned cytokines 
compared to healthy controls, which is also in line 
with the fact that no differences were observed in 
the whole blood mRNA expression between 
patients and controls.83,84 These discrepancies 
require further investigation but might represent 
differences in the environment (in vivo versus ex 
vivo) in that the cytokines were measured, in epi-
genetics modifications, or both.84
A recent study demonstrated that complement 
might have some role in HS.3 Kanni et al. showed 
that C5a and membrane attack complex C5b-9 
were increased in plasma of HS patients com-
pared with healthy individuals.3 In addition, in 
ex  vivo experiments they showed that blocking 
c5a was able to inhibit TNF production by 
patients’ PBMCs. These findings imply a central 
role of the complement in HS and possibly 
explain, at the same time, recruitment and activa-
tion of neutrophils at skin lesions.3
Microbiome and biofilms
Despite the clinical presentation of HS that 
resembles bacterial infection and the efficacy of 
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antimicrobials as a treatment modality, the role of 
bacteria remains controversial. To understand 
their role in the pathogenesis of HS and possibly 
identify new therapeutic targets, researchers tried 
to isolate bacteria from skin lesions in HS patients. 
No specific bacterial agent has been found so far, 
contrariwise a variety of microorganisms mostly 
part of the skin normal flora were identified. 
Gram-positive cocci and rods,85 including 
Staphylococcus aureus, coagulase-negative staphy-
lococci (CoNS), and Corynebacterium spp have 
been isolated from deep tissue samples. CoNS 
were the most common species found in cultures 
from deep lesions obtained by carbon dioxide 
laser treatment.86,87 Staphylococcus lugdunensis, a 
CoNS species, was associated with early stages of 
HS lesions (Hurley I).88 Anaerobic bacteria, pre-
dominantly Gram-negative rods Prevotella and 
Porphyromonas, were also identified in various 
early and chronic HS lesions.88,89 Using next-gen-
eration sequencing, it was demonstrated that 
there is a significantly different microbiome in 
patients with HS, either lesional or nonlesional, 
compared with that in healthy controls: 
Corynebacterium species (type I) or Porphyromonas 
and Peptoniphilus species (type IV) were the pre-
dominant species identified from HS lesions, 
whereas type IV was not detected in healthy con-
trols. This significant difference between both 
lesional and nonlesional HS skin microbiota and 
that in healthy controls, drives the hypothesis of a 
link between a dysbiotic cutaneous microbiome 
and HS.90
The formation of biofilm in chronic and acute HS 
lesions is not a surprising finding knowing that 
CoNS and the other commonly found in HS bac-
teria are known for their capability of biofilm for-
mation.91,92 The presence of the latter has 
implications both in the pathogenesis of HS, as 
well as in the choice of treatment. The chronic 
course with acute exacerbations in between, the 
need of prolonged treatment with the slow heal-
ing process of the lesions, the need for surgical 
debridement in severe stages, and the relative 
resistance towards classic antimicrobials are com-
patible with a biofilm-driven disease.93
Severity and scores of HS
In the last three decades, multiple scoring systems 
have been introduced in order to evaluate the sever-
ity of HS. The Harley staging system was proposed 
first in 1989 and it is still widely used in research 
and clinical practice. It uses clinical features such 
as the presence of abscesses, scarring, and sinus 
track formation to categorize HS patients into 
three distinct stages: stage I is characterized by 
abscess formation, single or multiple, without 
scarring or sinus tracts; stage II by recurrent 
abscesses single or multiple, widely separated 
lesions with scarring and tract formation; and 
stage III by diffuse or near-diffuse involvement, 
or multiple interconnected tracts and abscesses 
across the entire area.94 Hurley severity staging is 
helpful in therapeutic decisions, but it is not suit-
able for treatment evaluation during follow up. 
Thus, more dynamic HS scoring systems such as 
Sartorius score (later modified) and Physician 
Global Assessment (PGA) were proposed in 
order to assess treatment response better; an 
overwhelming need especially after the introduc-
tion of biologics into the treatment options.20,95 A 
more recent scoring system, Hidradenitis 
Suppurativa Clinical Response (HiSCR), is 
defined as at least a 50% reduction in total abscess 
and inflammatory nodule count with no increase 
in abscess and draining fistula count when com-
pared with baseline96 and has been used to assess 
the effectiveness of treatment with biologics. 
Furthermore, scale scores that consider the 
degree of pain, the number of flares, and the 
impact on quality of daily life in HS patients, such 
as the Dermatology Life Quality Index (DLQI) 
and Pain Visual Analog Scale, have been used to 
assess treatment effectiveness in both research 
and clinical settings.97 It is worth noting that not 
all the staging scores use biomarkers in the assess-
ment of either the severity or the treatment 
response. However, a study proposed that soluble 
interleukin-2 receptor (sIL-2R) serum level could 
be used as a valuable marker for disease staging in 
patients with HS.98 Finally, is worth mentioning 
that efforts have been made to establish a core 
outcome set in HS clinical trials.99
Treatment
Antibiotics
Systemic antibiotics used to be the cornerstone of 
HS treatment for decades. Both European100 and 
North American97 guidelines continue to recom-
mend as a considerable option the use of antimi-
crobial agents alone or in combinations at 
different stages of HS. Tetracyclines, clindamy-
cin, rifampicin, moxifloxacin, metronidazole, and 
ertapenem are the agents that have proved their 
efficacy in HS treatment. Not surprisingly, the 
regimens that have been proposed seem to share 
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more or less the same attributes: they are active 
against aerobic and anaerobic bacterial agents 
most commonly found in HS lesions, they pene-
trate and show antimicrobial activity in biofilms, 
and importantly possess significant anti-inflam-
matory and immunomodulatory properties.
Tetracyclines. Tetracycline and its second-gener-
ation semisynthetic analogs doxycycline and 
minocycline are recommended as monotherapy 
for mild stages of HS.97,100 They have a broad-
spectrum bacteriostatic activity against a variety 
of Gram-positive and Gram-negative bacteria by 
binding to the 30S ribosomal subunit, thereby 
halting bacterial protein synthesis. Doxycycline, 
the most commonly used tetracycline in HS, has 
been shown to have also the ability to penetrate 
S. aureus biofilm in high-enough concentrations 
to maintain its antibacterial activity.101 In addi-
tion, doxycycline, as with other tetracyclines, has 
a variety of anti-inflammatory and immunomod-
ulatory properties.102 It can reduce the produc-
tion of IL-1, IL-6, TNF-α, and IL-8, downregulate 
chemotaxis, promote lipo-oxygenase, MMP and 
nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) signaling inhibition.
Clindamycin, rifampicin. Clindamycin is the only 
antibiotic that has been studied for topical treat-
ment and can be used in mild localized stages of 
HS.103 It has also shown the same efficacy com-
pared with oral tetracycline.104 The systemic com-
bination of clindamycin and rifampicin is the 
most studied and its efficacy is well estab-
lished.105,106 It is widely offered in cases of tetra-
cycline failure in mild to moderate stages of 
HS.97,100 Clindamycin has a bacteriostatic activity 
against both aerobic and anaerobic Gram-positive 
bacteria by binding irreversibly to 50S ribosomal 
subunit, thereby inhibiting bacterial protein syn-
thesis. It has no potent antibiofilm effect101 and its 
anti-inflammatory properties are suggested in 
topical treatment against Acne vulgaris.107 How-
ever, the lack of both properties is balanced by the 
excellent antibiofilm activity of rifampicin as it 
has been proven in periprosthetic joint infec-
tions.101,108 Rifampicin binds to the 50s ribosomal 
subunit where it disrupts transpeptidation and 
thereby halts protein synthesis in a similar man-
ner to macrolides. It has a broad-spectrum activ-
ity mostly against Gram-positive and some 
Gram-negative bacteria as well. In addition, it is 
suggested that rifampicin possesses anti- 
inflammatory and immunomodulatory proper-
ties. There is evidence that it can reduce inducible 
nitric oxide synthase (iNOS) transcription and 
NF-κB activity, inhibit excessive Th17 responses, 
and thereby reduce their differentiation and 
secretion.109,110
Moxifloxacin, rifampicin, and metronidazole. This 
triple combination is appeared to be effective in 
reducing HS activity in moderate to severe cases 
that were refractory to other treatment.111 Moxi-
floxacin is a synthetic fluoroquinolone with a 
broad spectrum of activity against aerobic Gram-
positive and Gram-negative bacteria and has a 
potent activity against most of the anaerobic 
enteric pathogens. It is suggested that possesses 
anti-inflammatory properties as well, by reducing 
IL-1ß, IL-8, TNF-α, stabilizing IXb protein, sup-
pressing NF-κB signaling, and reducing IL-
17A.112,113 Metronidazole was added to increase 
the activity spectra; to cover some Gram-negative 
anaerobic bacteria that are naturally resistant or 
have intermediate susceptibility to moxifloxacin. 
In addition, combination of moxifloxacin with 
rifampicin alters the pharmacokinetics and the 
efficacy of moxifloxacin.
Ertapenem. Ertapenem is an intravenous broad-
spectrum β-lactam antibiotic that can be used to 
treat complicated skin and soft tissue infections114 
and is highly efficient in improving the clinical 
aspects of severe HS.115 However, it is recom-
mended to be used for a single 6-week course as 
rescue therapy or during surgical planning.97
Biologics
Given the role of TNF, IL-23, and IL-17 in the 
pathogenesis of HS, as outlined above, treatment 
with biologic disease-modifying antirheumatic 
drugs (DMARDs) has been successfully tried and 
are included as therapeutic options in moderate 
to severe HS, in the relevant European and North 
American guidelines.97,100 In fact, after several tri-
als, adalimumab has been approved for moderate 
to severe (Hurley stage II and III) HS. Of note, 
the dosing differs from schemes approved for 
other diseases such as RA, being 40 mg every 
week, after a loading dose of 160 mg and 80 mg 
at weeks 0 and 2, respectively.116
In the two largest phase-III trials (Pioneer I and 
II) for adalimumab in HS, involving 307 and 326 
patients, HiSCR was achieved at week 12 in 
41.8% and 58.9% of patients treated with adali-
mumab compared with 26.0% and 27.6% for pla-
cebo.117 Infliximab has also proven to be effective 
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in the treatment of HS,118 although more studies 
are needed. Interestingly, in a small retrospective 
study, infliximab in a dosing scheme of 5 mg/kg at 
weeks 0 and 2 performed better than adalimumab 
given at 40 mg every other week.119 That said, It 
has been suggested that a dosing scheme of inf-
liximab every 4 instead of every 8 weeks might be 
beneficial for HS patients.120 Results for other 
TNF inhibitors, such as certolizumab121 or 
etanercept, are either negative or inconclusive.116
Anakinra, an IL-1 receptor antagonist, is also a 
promising drug for this disease. The largest, thus 
far, trial for this regime has shown superiority ver-
sus placebo at week 12. HiSCR was achieved in 
78% and 30% of the patients (p = 0.04), respec-
tively. This difference wore off after 12 weeks 
without treatment.122
IL-23 is also a significant player in HS. That 
given, ustekinumab, which is a monoclonal anti-
body against the p40 subunit of IL-12 and IL-23, 
has been tried as a treatment modality. In the 
largest, thus far, open-label trial, 47% of HS 
patients treated with ustekinumab achieved 
HiSCR at week 40 and moderate to marked 
improvement was seen in 82% according to the 
modified Sartorius score.82 Furthermore, in a 
small retrospective study, guselkumab, which is a 
monoclonal antibody against p19 subunit of 
IL-23, at a dose of 100 mg at weeks 0 and 4 and 
every 8 weeks thereafter, proved to be effective in 
more than half (63%) of the HS patients treated.123 
Importantly, 7 out of 8 patients in the study had 
previously been treated with other antibiotics. 
The authors of this study suggested that higher 
doses might be even more effective. A phase-II 
multicenter trial is currently underway to test this 
drug in moderate to severe HS.121
Monoclonal antibodies against IL-17 have been 
also tried. A recently published open-label trial 
for patients receiving 300 mg of secukinumab 
weekly for 5 weeks, then every 4 weeks reported 
that 78% of the patients achieved HiSCR at week 
24.124 In addition, clinical trials are underway to 
test the safety and efficacy of this secukinumab 
and bimekizumab (monoclonal antibody against 
IL-17a and IL-17F) in moderate to severe HS.121
Finally, apremilast, which is an inhibitor of phos-
phodiesterase-4 (PDE4) approved for psoriasis 
and PsA, has shown some efficacy in HS. In a 
placebo-controlled trial, 53% of HS patients at 
30 mg of apremilast, twice a day, achieved HiSCR 
at week 16 compared with none of placebo 
(p = 0.055).125
In general, treatment for HS is not clearly defined 
and is based on anecdotal evidence and expert 
opinion.126 As a general approach, systemic or 
topical antibiotics are used. However, in moderate 
to severe disease or when antibiotics discontinua-
tion leads to disease flares, treatment with biologic 
drugs or other immunosuppressives is sug-
gested.126 Short-term glucocorticoids can also be 
used as a bridging or adjuvant therapy.97 Surgical 
treatment is used alone or usually in combination 
with medical treatment, as outlined previously.
Conclusion
HS is not as rare as previously thought, affecting 
0.5–4% of the general population. Its pathogene-
sis is still largely unclear. However, it seems that a 
combination of genetic factors and skin microbi-
ome alterations play a role. TNF, IL-23/IL-17 
axis, and IL-1 seem to also play a significant role, 
which is mirrored in the efficacy of TNF inhibi-
tors and other biologics in the treatment of HS. 
Links between HS and autoimmune conditions 
have been demonstrated, with an increased prev-
alence of HS in some antirheumatic drugs and 
common associations with comorbidities of the 
metabolic spectrum. Future epidemiologic stud-
ies in large HS or antirheumatic drug cohorts will 
clarify this issue and might elucidate more the 
pathogenesis of the former.
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